- Home
- ZLAB vs EXEL Comparison
ZLAB vs EXEL Comparison
Compare ZLAB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- EXEL
- Stock Information
- Founded
- ZLAB 2013
- EXEL 1994
- Country
- ZLAB China
- EXEL United States
- Employees
- ZLAB N/A
- EXEL N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZLAB Health Care
- EXEL Health Care
- Exchange
- ZLAB Nasdaq
- EXEL Nasdaq
- Market Cap
- ZLAB 3.5B
- EXEL 9.8B
- IPO Year
- ZLAB 2017
- EXEL 2000
- Fundamental
- Price
- ZLAB $31.84
- EXEL $38.55
- Analyst Decision
- ZLAB Buy
- EXEL Buy
- Analyst Count
- ZLAB 4
- EXEL 18
- Target Price
- ZLAB $47.37
- EXEL $37.59
- AVG Volume (30 Days)
- ZLAB 1.7M
- EXEL 2.4M
- Earning Date
- ZLAB 05-08-2025
- EXEL 05-09-2025
- Dividend Yield
- ZLAB N/A
- EXEL N/A
- EPS Growth
- ZLAB N/A
- EXEL 170.77
- EPS
- ZLAB N/A
- EXEL 1.76
- Revenue
- ZLAB $398,988,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- ZLAB $44.43
- EXEL $5.78
- Revenue Next Year
- ZLAB $48.68
- EXEL $10.94
- P/E Ratio
- ZLAB N/A
- EXEL $21.91
- Revenue Growth
- ZLAB 49.59
- EXEL 18.50
- 52 Week Low
- ZLAB $15.65
- EXEL $20.14
- 52 Week High
- ZLAB $39.77
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- ZLAB 49.33
- EXEL 61.01
- Support Level
- ZLAB $28.34
- EXEL $35.34
- Resistance Level
- ZLAB $34.59
- EXEL $38.57
- Average True Range (ATR)
- ZLAB 1.82
- EXEL 1.14
- MACD
- ZLAB 0.35
- EXEL 0.31
- Stochastic Oscillator
- ZLAB 73.43
- EXEL 93.70
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.